Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
Bilger G, Toffart AC, Darrason M, Duruisseaux M, Ulmer L, Wang P, Leprieur EG, Girard N, Massiani MA, Bore P, Descourt R, Pinsolle J, Valery S, Monnet I, Swalduz A, Tissot C, Fournel P, Baranzelli A, Cortot AB, Decroisette C. Bilger G, et al. Among authors: massiani ma. Ther Adv Med Oncol. 2022 Jun 6;14:17588359221099399. doi: 10.1177/17588359221099399. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35694190 Free PMC article.
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab.
Seban RD, Assié JB, Giroux-Leprieur E, Massiani MA, Soussan M, Bonardel G, Chouaid C, Playe M, Goldfarb L, Duchemann B, Mezquita L, Girard N, Champion L. Seban RD, et al. Among authors: massiani ma. Cancers (Basel). 2020 Aug 10;12(8):2234. doi: 10.3390/cancers12082234. Cancers (Basel). 2020. PMID: 32785166 Free PMC article.
Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Mayenga M, Assié JB, Monnet I, Massiani MA, Tabeze L, Friard S, Fraboulet S, Métivier AC, Chouaïd C, Zemoura L, Longchampt E, Callens C, Melaabi S, Couderc LJ, Doubre H. Mayenga M, et al. Among authors: massiani ma. Lung Cancer. 2020 Dec;150:21-25. doi: 10.1016/j.lungcan.2020.09.008. Epub 2020 Sep 16. Lung Cancer. 2020. PMID: 33045465
Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients.
Basse C, Diakite S, Servois V, Frelaut M, Noret A, Bellesoeur A, Moreau P, Massiani MA, Bouyer AS, Vuagnat P, Malak S, Bidard FC, Vanjak D, Kriegel I, Burnod A, Bilger G, Ramtohul T, Dhonneur G, Bouleuc C, Cassoux N; Institut Curie COVID Group,; Paoletti X, Bozec L, Cottu P. Basse C, et al. Among authors: massiani ma. JNCI Cancer Spectr. 2021 Jan 6;5(1):pkaa090. doi: 10.1093/jncics/pkaa090. eCollection 2021 Feb. JNCI Cancer Spectr. 2021. PMID: 33604509 Free PMC article.
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
Seban RD, Assié JB, Giroux-Leprieur E, Massiani MA, Bonardel G, Chouaid C, Deleval N, Richard C, Mezquita L, Girard N, Champion L. Seban RD, et al. Among authors: massiani ma. Lung Cancer. 2021 Sep;159:45-55. doi: 10.1016/j.lungcan.2021.06.024. Epub 2021 Jul 20. Lung Cancer. 2021. PMID: 34311344
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy.
Chelabi S, Mignard X, Leroy K, Monnet I, Brosseau S, Theou-Anton N, Massiani MA, Friard S, Duchemann B, Fabre E, Giroux-Leprieur E, Cadranel J, Wislez M. Chelabi S, et al. Among authors: massiani ma. Cancers (Basel). 2021 Oct 13;13(20):5132. doi: 10.3390/cancers13205132. Cancers (Basel). 2021. PMID: 34680280 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 34701789
30 results